Dhakhtarkaaga ayaa u badan inuu kuu sheego inaad qaadatid asbiriin maalinle ah si uu u yareeyo khatarta aad ugu jirto cudurka wadnaha ama istaroog . Aspirin wuxuu u shaqeeyaa isagoo faragalinaya awoodda dhiigaaga ee ku haboon inuu abuuro xinjiro khatar ah, sidaas darteedna ka caawinaya ka hortagga weerarka wadnaha iyo faaliga. Si kastaba ha ahaatee, qaadashada aspirin ma ahan halis la'aan. Aspirin wuxuu sababi karaa calool-xanuun iyo dhiig-ay ku jiraan dhiig-gubashada, dhiigga, iyo dhiig-baxa, iyo xitaa dhiig-baxa maskaxda.
Sidaa darteed qaadashada asbiriin maalin walba waxaa lagula taliyaa kaliya marka faa'iidooyinka ay u badan tahay in ay aad uga culus yihiin halista suurtagalka ah ee qof gaar ah.
Aspirin maalin walba waxaa lagu taliyaa dadka qaba cudurka wadnaha ama stroke, kuwaas oo qaba cudurka halbowlaha wadnaha, ama qatarta uu ku yeelan karo cudurka wadnaha iyo sanbabada sanadaha soo socda ayaa la go'aamiyaa in uu sarreeyo. Si kastaba ha noqotee, go'aanka qaadashada asbiriin maalinle ah waa in uu shakhsiyan yahay, had iyo jeer waa in laga hadlo dhakhtarkaaga. Waa muhiim in aad wax dheeraad ah ka ogaatid in qaadashada asbiriin maalinle ah ay kugu habboon tahay.
Aspirin iyo Ibuprofen Ha isku qasin
Sida laga soo xigtay Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA), Ibuprofen wuxuu faragelin karaa saameynta ladagaallanka xinjirta (aspirin) (qiyaas ahaan 81 mg maalintii), taasoo suurta gal ah in asbiriinku waxtar ka yaryahay marka loo isticmaalo in lagu caawiyo ilaalinta wadnahaaga iyo caawimadaada ka hortagaa istaroog.
FDA waxay ku talineysaa in aad tixgeliso kuwan soo socda:
- Haddii aad isticmaasho ibuprofen marmar, waxaa jira halis yar oo ah in Ibuprofen uu faragelin doono saameynta daawada asaasiga ah ee hooseeya.
- Haddii aad u baahan tahay hal qiyaas oo hal ah ibuprofen, qaado 8 saacadood ka hor ama 30 daqiiqo ka dib markaad qaadato daawo joogto ah (aan aheyn xidid dhexdhexaad ah) aspirin.
- Haddii aad u baahato in aad qaadato ibuprofen marar badan, kala hadal dhakhtarkaaga wixii ku saabsan daawooyinka kale. Dhakhtarkaagu wuxuu kugula talin karaa xanuun joojiye aan faragelinin saameynta daawada asaasiga ah ee hooseeya.
Ibuprofen waxaa iska leh daawooyinka loo yaqaan NSAID (daawooyinka aan anti-inflammatory ahayn). Waa inaadan qaadanin NSAID kale (sida daawooyinka ay ku jiraan naproxen) adiga oo aan la hadlin dhakhtarkaaga, maaddaama qaar kale NSAIDs ay yeelan karaan fursad ay ku faragaliyaan saameynta ilaalinta qaadashada daawada hoose ee aspirin.
Ibuprofen iyo Noocyada kala duwan ee Aspirin
Talooyinka FDA waa mid caadi ah (oo sidoo kale loogu yeero si dhakhso ah loo sii daayo) Aspirin-qiyaas yar (81 mg). Awoodda Ibuprofen ee faragelinta saameynta lidka-ka-xinjirta ee aspirin-ku-xidhan ama qiyaaso badan oo aspirin ah (sida asbirin weyn oo ah aspirin-325 mg) lama yaqaan.
Qadka hoose: Si aad u noqotid dhinaca nabdoonaanta iyo ka hortagga daroogada aan la rabin, waa inaad had iyo jeer la hadashaa dhakhtarkaaga ama farmashiistaha ka hor intaadan qaadin daawooyinka xanuunka miisaanka (OTC) ee dawada haddii aad isticmaalayso asbiriin nooc kasta.
Ibuprofen iyo Acetaminophen
Si ka duwan sida aspirin iyo ibuprofen, oo aan la isku darin, Ibuprofen (sida Motrin) iyo acetaminophen (sida Tylenol) ayaa la isku dari karaa.
Dhab ahaantii, natiijooyinka ka soo baxay daraasad yar oo lagu daabacay "Journal Journal of Anesthesia" waxay soo jeedinaysaa in marka Ibuprofen iyo acetaminophen la isu geeyo (qaabka loo yaqaan 'Maxigesic') oo ay ka qaybgalayaashu ahaayeen qalliin afka ah, gargaarid.
> Isha:
> Borazan NH, Furst DE. Mukhaadaraadka Ka-hortagga Daroogada, Daroogada-Is-beddelka Mukhaadaraadka Qalabka Nadaafadeed, Qalabka Cudurka Qalafsanaanta, iyo Daroogooyinka loo isticmaalo Gout. In: Katzung BG, Trevor AJ. eds. Farmashiga Aasaasiga ah & Daaweynta, 13e . New York, NY: McGraw-Hill; 2015.
> Merry AF, Gibbs RD, Edwards J, et al. Acetaminophen iyo ibuprofen oo loogu talagalay gargaarka xanuunka ka dib markii qalliinka afka laga sameeyo qaangaarka: tijaabo kontaroolan oo la kala sooco. British Journal of Anesthesia , 2010 Jan; 104 (1): 80-88.